Source: Fortune
Summary
Fidji Simo, former CEO of AGI Deployment at OpenAI, has left her role to focus on her health and a new startup, ChronicleBio. The company aims to use AI to find cures for chronic diseases, including Postural Orthostatic Tachycardia Syndrome (POTS), which Simo herself suffers from. ChronicleBio has raised $15 million and has collected 153 terabytes of data from 709 patients. The company plans to launch a mobile phlebotomy service to collect blood samples from patients with chronic diseases, with the goal of identifying sub-diseases and developing targeted treatments.
Our Reading
The numbers tell one story. Fidji Simo’s departure from OpenAI and her new venture, ChronicleBio, highlight the challenges of addressing chronic diseases. With $15 million in funding, ChronicleBio is taking a data-driven approach to identify sub-diseases and develop targeted treatments. The company’s use of AI and mobile phlebotomy services aims to improve the success rate of clinical trials and provide hope for patients with conditions like POTS.
One original observation: The intersection of AI and healthcare is not just about technology, but about the human cost of chronic diseases and the need for innovative solutions.
Author: Evan Null
